drugset
drugset / Trial / NCT07564232

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

NCT07564232 ↗

Phase 1 Recruiting 40 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC. The goal of Part 2 is to learn if the recommended dose of LNK001 found in Part 1 can help to control the disease.

Timeline

Start
2026-07-02
Primary completion
2031-06-06
Completion
2033-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LNK001 Cell therapy — Other
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

clear cell renal carcinoma